Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
37.45
-0.17 (-0.45%)
At close: Feb 27, 2026, 4:00 PM EST
37.49
+0.04 (0.10%)
After-hours: Feb 27, 2026, 7:59 PM EST
Novo Nordisk Revenue
In the year 2025, Novo Nordisk had annual revenue of 309.06B DKK with 6.43% growth. Novo Nordisk had revenue of 79.14B in the quarter ending December 31, 2025, a decrease of -7.63%.
Revenue (ttm)
309.06B DKK
Revenue Growth
+6.43%
P/S Ratio
3.44
Revenue / Employee
4,446,644 DKK
Employees
69,505
Market Cap
167.25B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Bristol-Myers Squibb Company | 48.19B |
NVO News
- 5 hours ago - Novo Nordisk (NVO) Faces Tough Month Amid Competitive Pressures - GuruFocus
- 10 hours ago - Benzinga Bulls And Bears: Rocket Lab, Kosmos Energy, Novo Nordisk — And Nvidia Fails To Boost Markets - Benzinga
- 15 hours ago - Anthropic vs. The Pentagon: what enterprises should do - VentureBeat
- 1 day ago - FDA Approves Novo Nordisk's Sogroya for New Pediatric Indications (NVO) - GuruFocus
- 1 day ago - Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival - GuruFocus
- 1 day ago - Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks - Seeking Alpha
- 1 day ago - Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making - The Motley Fool
- 1 day ago - Novo Nordisk: A Trap, Not A Trade (Rating Upgrade) - Seeking Alpha